Imperial College London

Dr Tony Goldstone

Faculty of MedicineDepartment of Brain Sciences

Senior Clinical Research Fellow



+44 (0)20 7594 5989tony.goldstone Website




E313Burlington DanesHammersmith Campus





  • Foster/Schauer Award, The Obesity Society, 2015
  • Travel Award, The Endocrine Society's 91st Annual Meeting, Washington DC, USA, 2009
  • Travel Award, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Neuroimaging in Obesity Research Conference, NIH, Bethseda, USA, 2008
  • Poster Prize, 5th European Nutrigenomics Organisation (NUGO) Conference, Potsdam, Germany, 2008
  • Value in People Award, Wellcome Trust, 2006
  • Clinical Poster Prize, 36th International Growth Hormone Symposium, Geneva, Switzerland, 2004
  • GMJ Slot Prize for Fellowship report, Royal College of Physicians, London, 2000
  • European Science Exchange Programme Award, The Royal Society, London, 1998
  • Young Scientist Award, 3rd Prader-Willi Syndrome International Conference, Italy, 1998

External Positions

  • Member, Nutrition Network, European College of Neuropsychopharmacology, European College of Neuropsychopharmacology, 2017
  • Member, Programme Committee, The Society for the Study of Ingestive Behavior, The Society for the Study of Ingestive Behavior, 2017
  • Medical Advisor, International Prader-Willi Syndrome Organisation, International Prader-Willi Syndrome Organisation, 2017
  • Member, Data Montoring Committee, Phase 2 clinical trials: “Effect of liraglutide for weight management in paediatric patients with Prader-Willi syndrome”; “Effect of liraglutide for weight management obese pubertal adolescent subjects", NovoNordisk, 2016
  • Member, Scientific Committee, Prader-Willi Syndrome Expert Meeting, Toulouse, France, 2014 - 2014
  • Member, Scientific Committee, 8th Prader-Willi Syndrome International Conference, Cambridge, UK, International Prader-Willi Syndrome Association, 2013 - 2013
  • Member, Scientific Committee, 2nd International Hyperphagia Conference, 2nd International Hyperphagia Conference, Pennington Biomedical Research Centre, Baton Rouge, USA, 2012 - 2012
  • member, International consensus conference ‘Use of GH for the treatment of infants, children and adults with Prader-Willi Syndrome', Montreal, Canada, Growth Hormone Research Society, 2011 - 2011
  • Organiser and Scientific Co-Chair,, Scientific Committee, 1st International Hyperphagia Conference, 1st International Hyperphagia Conference, Baltimore USA, 2009 - 2009
  • Member, UK Biobank Imaging Enhancement Working Group, UK Biobank, 2009
  • Member, Scientific Committee, 6th Prader-Willi Syndrome International Conference, Cluj, Romania, International Prader-Willi Syndrome Organisation, 2007 - 2007
  • Member, Scientific Committee, 2nd Prader-Willi Syndrome Expert Meeting, Toulouse France, 2006 - 2006

Membership of Professional Bodies

  • British Feeding and Drinking Group, British Feeding and Drinking Group, 2016
  • Member, Society for the Study of Ingestive Behavior, 2013
  • Member, Society for Neuroscience, 2012
  • Member, The Obesity Society, 2005
  • Member, American Endocrine Society, 2000
  • Member, Society for Endocrinology, 2000

Industrial Connections

  • Levo Therapeutics, Consultant, LV-201 for treatment of Prader-Willi Syndrome
  • Merck Research Laboratories, Rahway, NJ, USA, Obesity Consultant,
  • Millendo Therapeutics, Member, Clinical Advisory Board, Livoletide for treatment of Prader-Willi syndrome
  • Rythym Pharmaceuticals, Use of Setmelanotide for treatment of genetic obesity
  • Soleno Therapeutics, Consultant, developing Diazoxide for treatment of Prader-Willi syndrome
  • Zafgen, Use of Beloranib for treatment of Prader-Willi syndrome


  • Fellow of The Obesity Society, The Obesity Society, 2017
  • Samuel Leonard Simpson Fellowship in Endocrinology, Royal College of Physicians, 1999 - 1999
  • MRC Clinical Training Fellowship, UK Medical Research Council, 1995 - 1999